Chetan Prasad, MD
Internal Medicine · Davenport, IANPI 1962884361
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $277 and has fallen 79.4% since, to $57 in 2025.
Across 60 payments — averaging $16.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$137
- AstraZeneca$94
- Pfizer$83
- Lilly USA, LLC$82
- GSK$78
- Exact Sciences$71
- plus $451 from 14 others
What the payments were for
- Food & beverage$996100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $137 |
| AstraZeneca | 6 | $94 |
| Pfizer | 5 | $83 |
| Lilly USA, LLC | 5 | $82 |
| GSK | 5 | $78 |
| Exact Sciences | 4 | $71 |
| Dexcom, Inc. | 3 | $71 |
| Sanofi-aventis U.S. LLC | 5 | $64 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| AbbVie | 3 | $61 |
| Bayer | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Indivior Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $14 |
| Novartis | 1 | $14 |
| Merck | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$996 in reported general payments places this provider in the 85th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 154 | $180,790 |
| TrulicityDulaglutide | 142 | $151,954 |
| OzempicSemaglutide | 118 | $132,579 |
| EliquisApixaban | 85 | $97,348 |
| JanuviaSitagliptin Phosphate | 28 | $27,382 |
| SymbicortBudesonide/Formoterol Fumarate | 92 | $23,899 |
| Breo ElliptaFluticasone/Vilanterol | 42 | $21,221 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $18,799 |
| TradjentaLinagliptin | 19 | $18,323 |
| EntrestoSacubitril/Valsartan | 13 | $14,346 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $13,978 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,342 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $9,982 |
| Humalog Kwikpen U-100Insulin Lispro | 42 | $8,968 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 19 | $8,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $13 | $199,112173 claims |
| Lilly USA, LLCTrulicity | $82 | $151,954142 claims |
| Novo NordiskOzempic, Novolog | $137 | $135,273129 claims |
| PfizerEliquis | $83 | $97,34885 claims |
| GSKBreo Ellipta, Incruse Ellipta, Anoro Ellipta | $78 | $51,362103 claims |
| AstraZenecaSymbicort, Bevespi Aerosphere | $94 | $33,880106 claims |
| MerckJanuvia | $14 | $27,38228 claims |
| NovartisEntresto | $14 | $14,34613 claims |
| AbbVieCreon | $61 | $1,43017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in Davenport
- Alex SiegDavenport$4K
- Radhika KollaDavenport$3K
- James HahnDavenport$1K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.